Calypso study ovarian cancer

Final overall survival results of phase III GCIG CALYPSO ...

★ ★ ★ ☆ ☆

8/7/2012 · Patients and methods. The patients, methods, and design of CALYPSO were previously reported (Pujade-Lauraine et al, 2010).Briefly, patients had ovarian cancer that recurred >6 months after first- or second-line platinum-based chemotherapy and had received a taxane.

Final overall survival results of phase III GCIG CALYPSO ...

Final overall survival results of phase III GCIG CALYPSO ...

★ ★ ★ ☆ ☆

8/7/2012 · 1. Br J Cancer. 2012 Aug 7;107(4):588-91. doi: 10.1038/bjc.2012.307. Epub 2012 Jul 26. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients.

Final overall survival results of phase III GCIG CALYPSO ...

CALYPSO trial shows new chemotherapy combination prolongs ...

★ ★ ☆ ☆ ☆

10/20/2009 · CALYPSO trial shows new chemotherapy combination prolongs progression free survival in ovarian cancer 20 Oct 2009 Treating women with relapsed platinum-sensitive ovarian cancer with combined carboplatin and pegylated liposomal doxorubicin prolongs progression free survival and is associated with a lower risk of severe, long lasting nerve damage ...

CALYPSO trial shows new chemotherapy combination prolongs ...

Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin ...

★ ★ ★ ★ ★

9/19/2005 · Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse (CALYPSO) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.

Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin ...

Ovarian cancer in elderly patients: carboplatin and ...

★ ★ ★ ★ ★

7/26/2012 · The patients, methods, and design of CALYPSO were previously reported (Pujade-Lauraine et al, 2010).Briefly, patients had ovarian cancer that recurred >6 months after first- or second-line ...

Ovarian cancer in elderly patients: carboplatin and ...

Final overall survival results of phase III GCIG CALYPSO ...

★ ★ ★ ★ ★

1/30/2012 · Study previously presented at the 2010 American Society of Clinical Oncology Annual Meeting: Brundage M, Gropp M, Mefti F et al. Health-related quality of life (HRQL) and progression-free survival (PFS) in patients with recurrent ovarian cancer: results from the CALYPSO trial. J Clin Oncol 2010; 28 (Suppl): 15s (Abstr 5044). references

Final overall survival results of phase III GCIG CALYPSO ...

Health-related quality of life in recurrent platinum ...

★ ★ ★ ★ ★

1/12/2012 · Main eligibility criteria of GCIG CALYPSO study. As reported elsewhere, patients with cancer of the ovary or fallopian tube or extra-ovarian papillary serous carcinoma who experienced disease ...

Health-related quality of life in recurrent platinum ...

CA-125 can be part of the tumour evaluation criteria in ...

★ ★ ☆ ☆ ☆

Based on the findings from these trials, the Gynecologic Cancer InterGroup (GCIG) conducted the CALYPSO study (NCT00189553), an international phase III study that compared standard carboplatin and paclitaxel (CP) with carboplatin and pegylated liposomal doxorubicin – PLD (CD) in patients with platinum-sensitive ROC . The trial, which was ...

CA-125 can be part of the tumour evaluation criteria in ...

Carboplatin and pegylated liposomal doxorubicin versus ...

★ ★ ★ ☆ ☆

Ovarian Cancer: Recurrent Disease • All trials now focus on PFS • Nothing we have done in ovarian cancer recurrent disease treatment has increased OS in the last 10 years • Treating a patient at the time of biochemical or radiologic recurrence without presence of symptoms does not improve OS

Carboplatin and pegylated liposomal doxorubicin versus ...

Landmark Trials in Ovarian Cancer - Saint Agnes Medical Center

★ ★ ☆ ☆ ☆

A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG). Journal of Clinical Oncology. 2009 ASCO Annual Meeting, 2009; Vol. 27:18s (suppl; abstr LBA5509).

Landmark Trials in Ovarian Cancer - Saint Agnes Medical Center

Pegylated liposomal doxorubicin for relapsed epithelial ...

★ ★ ☆ ☆ ☆

1/7/2010 · Background. Platinum-based combinations are the standard second-line treatment for platinum-sensitive ovarian cancer (OC). This randomized phase II study was undertaken in order to compare the combination of carboplatin and pegylated liposomal doxorubicin (LD) with carboplatin and paclitaxel (CP) in this setting.

Pegylated liposomal doxorubicin for relapsed epithelial ...

A randomized phase II study of carboplatin plus pegylated ...

★ ★ ★ ☆ ☆

The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: Data from CALYPSO trial (a GINECO-GCIG study) ... et al.Development of a nomogram to predict progression-free survival in patients with platinum-sensitive …

A randomized phase II study of carboplatin plus pegylated ...

The strong prognostic value of KELIM, a model-based ...

★ ★ ☆ ☆ ☆

Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study

The strong prognostic value of KELIM, a model-based ...

(𝗣𝗗𝗙) Ovarian cancer in elderly patients: carboplatin and ...

★ ★ ☆ ☆ ☆

Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients

(𝗣𝗗𝗙) Ovarian cancer in elderly patients: carboplatin and ...

(PDF) Final overall survival results of phase III GCIG ...

★ ★ ★ ★ ☆

28 Second-Line Treatment of Ovarian Cancer completing initial therapy should be considered “platinum-resistant.” Persistent ovarian cancer is the finding of residual disease in a patient who has completed, and apparently responded to,

(PDF) Final overall survival results of phase III GCIG ...

Second-Line Treatment of Ovarian Cancer - The Oncologist

★ ★ ☆ ☆ ☆

6/11/2011 · Bevacizumab Halves Progression Risk in Recurrent Ovarian Cancer Elsevier Global Medical News. 2011 Jun 5, S London. CHICAGO (EGMN) - Adding the antiangiogenic agent bevacizumab to platinum-based chemotherapy halves the risk of progression in women with recurrent ovarian, peritoneal, or fallopian tube cancer, new data show.

Second-Line Treatment of Ovarian Cancer - The Oncologist

OCEANS study: Bevacizumab (Avastin) Halves Progression ...

★ ★ ☆ ☆ ☆

7/21/2010 · Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer (DESKTOP III) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.

OCEANS study: Bevacizumab (Avastin) Halves Progression ...

Study Comparing Tumor Debulking Surgery Versus ...

★ ★ ★ ★ ☆

that cancer relapse at the discretion of their gynaecologic oncologist. Information about the date of surgery and pre-operative extent of disease (tumour size, number of sites of metastasis) was not available for our analysis. Table 1 Baseline characteristics of patients at enrolment in the CALYPSO study. Characteristics Surgery No surgery P

Study Comparing Tumor Debulking Surgery Versus ...

Impact of secondary cytoreductive surgery on survival in ...

★ ★ ☆ ☆ ☆

CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: Experience of the GCIG CALYPSO trial. British Journal of Cancer, 2012 ... Management of asympto- platin treatment in the CALYPSO study. J Natl Cancer Inst 103: 1338 – 1342 matic patients on follow-up for ovarian cancer with rising CA-125 Pujade-Lauraine E, Wagner U ...

Impact of secondary cytoreductive surgery on survival in ...

(PDF) CA-125 can be part of the tumour evaluation criteria ...

★ ★ ★ ☆ ☆

The results of this analysis from the randomized phase III CALYPSO study, conducted in relapsed/recurrent ovarian cancer, confirm that reintroduction of carboplatin-based chemotherapy in patients with platinum-sensitive ovarian cancer is associated with a high rate of hypersensitivity (23.6%).

(PDF) CA-125 can be part of the tumour evaluation criteria ...

Decreased hypersensitivity reactions with carboplatin ...

★ ★ ★ ★ ★

Home / Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.

Decreased hypersensitivity reactions with carboplatin ...

Ovarian cancer in elderly patients: carboplatin and ...

★ ★ ★ ☆ ☆

View This Abstract Online; Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.

Ovarian cancer in elderly patients: carboplatin and ...

Ovarian cancer in elderly patients: carboplatin and ...

★ ★ ★ ★ ★

Study hypothesis. No data are available comparing trabectedin + PLD to a platinum-based regimen. Based on data from OVA-301 and CALYPSO the proposed INOVATYON trial will investigate the role of a non-platinum combination for the treatment of ovarian cancer patients relapsing between six and 12 months after last platinum-based chemotherapy 1 ...

Ovarian cancer in elderly patients: carboplatin and ...

Inovatyon second-line chemotherapy ovarian cancer - ISRCTN

★ ★ ★ ★ ☆

E. Pujiade-Lauraine, S. Mahner, J. Kaern et al., “A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Inter Group (GCIG),” in Proceedings of the ASCO Annual Meeting, 2009, abstract no. #5509.

Inovatyon second-line chemotherapy ovarian cancer - ISRCTN

Treatment for Recurrent Ovarian Cancer -At First Relapse

★ ★ ★ ☆ ☆

10/25/2018 · Adding pazopanib, a kinase inhibitor, to the standard postsurgical chemotherapy regimen has shown promise for progression-free survival in advanced ovarian cancer. In a study of 940 women with advanced ovarian cancer (epithelial ovarian, fallopian tube, or primary peritoneal cancers) who had not shown evidence of postsurgical progression after ...

Treatment for Recurrent Ovarian Cancer -At First Relapse

Ovarian Cancer Treatment & Management: Approach ...

★ ★ ★ ★ ☆

1/14/2019 · Treatment protocols for ovarian cancer are provided below, including the following: Treatment by stage Treatment of patients with implants Consolidation therapy Treatment of recurrent disease General treatment approach Surgery is the initial modality of treatment for stage I-IVA epithelial ovarian cancer. Only a small percentage of women ...

Ovarian Cancer Treatment & Management: Approach ...

Ovarian Cancer Treatment Protocols - Medscape Reference

★ ★ ☆ ☆ ☆

4/16/2013 · Emerging therapies in the management of ovarian cancer have resulted in a shift in paradigm, including in the appropriate time to institute therapy, and in the selection of therapy. This review focuses on chemotherapy and emerging biologic agents that present a therapeutic option for patients with recurrent ovarian cancer.

Ovarian Cancer Treatment Protocols - Medscape Reference

Recurrent Epithelial Ovarian Cancer: An Update on Treatment

★ ★ ★ ☆ ☆

7/15/2010 · Epithelial ovarian cancer is the leading cause of death from gynecologic malignancy in the United States, with approximately 15,000 deaths per year. Platinum/taxane doublets have long been considered the standard treatment regimen for advanced-stage disease; however, recent studies have sought to improve on the outcome from this therapy.

Recurrent Epithelial Ovarian Cancer: An Update on Treatment

New Advances in Ovarian Cancer | Cancer Network

★ ★ ★ ☆ ☆

A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG) [abstract]. Gynecol Oncol. 2009; 27 (18S): 799s. Abstract LBA5509.

New Advances in Ovarian Cancer | Cancer Network

The relevant distinction between “progression” in ovarian ...

★ ★ ★ ★ ★

CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial. Alexandre J, Brown C, Coeffic D, Raban N, Pfisterer J, Mäenpää J, Chalchal H, Fitzharris B, Volgger B, Vergote I, Pisano C, Ferrero A, Pujade-Lauraine E. Br J Cancer. 2012 Feb 14;106(4):633-7. doi: 10.1038/bjc.2011.593.

The relevant distinction between “progression” in ovarian ...

Publications from the Calypso Study – Nordic Society of ...

★ ★ ★ ★ ★

The CALYPSO study is a large Phase III trial comparing the safety and efficacy of a newer chemotherapy combination, carboplatin with liposomal doxorubicin (CPLD) with that of carboplatin-paclitaxel (CP) in patients with recurrent ovarian cancer.

Publications from the Calypso Study – Nordic Society of ...

Chemotherapy side effects can predict progression-free ...

★ ★ ★ ★ ★

This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of ovarian epithelial, fallopian tube, and primary peritoneal cancer. It is intended as a resource to inform and assist clinicians who care for cancer patients.

Chemotherapy side effects can predict progression-free ...

Ovarian Epithelial, Fallopian, & Peritoneal Cancer ...

★ ★ ☆ ☆ ☆

Clinical Trials in Ovarian Cancer Christine S. Walsh Published by Rutgers University Press Walsh, S.. Clinical Trials in Ovarian Cancer. New Brunswick: Rutgers University Press, 2017.

Ovarian Epithelial, Fallopian, & Peritoneal Cancer ...

Clinical Trials in Ovarian Cancer - muse.jhu.edu

★ ★ ★ ★ ☆

Ovarian cancer survival, high recurrence rates, and toxicity of current treatment regimens have led researchers to strive for improvements in first-line treatment. This review brings you up-to-date.

Clinical Trials in Ovarian Cancer - muse.jhu.edu

First-Line Treatment of Advanced Ovarian Cancer - Medscape

★ ★ ★ ★ ★

The standard initial management of epithelial ovarian cancer consists of surgical staging, operative tumour debulking including total abdominal hysterectomy and bilateral salpingo-oophorectomy, and administration of six cycles of intravenous chemotherapy with carboplatin and paclitaxel. Extensive and largely retrospective experience has shown that optimum surgical debulking to leave residual ...

First-Line Treatment of Advanced Ovarian Cancer - Medscape

Ovarian cancer - The Lancet

★ ★ ★ ★ ☆

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients With Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens (QUADRA) Niraparib shows promising activity in late-line treatment setting

Ovarian cancer - The Lancet

Ovarian Cancer Clinical Trials: Recurrence 6+ Months After ...

★ ★ ★ ☆ ☆

This trial is the first phase 2 study assessing the efficacy of PARP inhibitors in combination with anti-angiogenic agents for patients with recurrent platinum-sensitive ovarian cancer and mutated, wild-type, or unknown BRCA status. Median PFS of 17·7 months in the combination group is encouraging compared with median PFS reported in trials using platinum-based chemotherapy with and without ...

Ovarian Cancer Clinical Trials: Recurrence 6+ Months After ...

Combining targeted therapies in ovarian cancer - The ...

★ ★ ★ ☆ ☆

CALYPSO Study Schema Ovarian cancer in late relapse (> 6 months) after 1st-or 2 nd-line platinum-based therapy (previous taxane required) International, Intergroup, Open-label, Randomized Phase III Study R A N D O M I Z E Experimental arm: CD PLD 30 mg/m2 IV d 1 Carboplatin AUC 5 d 1 Control arm: CP Paclitaxel 175 mg/m2 IV d 1 Carboplatin AUC 5 d 1

Combining targeted therapies in ovarian cancer - The ...

New Developments in the Treatment of Recurrent Ovarian ...

★ ★ ★ ★ ☆

2/13/2012 · Ovarian cancer is the most lethal gynecologic malignancy. It appears that the vast majority of what seem to be primary epithelial ovarian and primary peritoneal carcinomas is, in fact, secondary from the fimbria, the most distal part of the fallopian tube. Treatment of epithelial ovarian cancer is based on the combination of cytoreductive surgery and combination chemotherapy using taxane and ...

New Developments in the Treatment of Recurrent Ovarian ...

Therapeutic strategies in epithelial ovarian cancer ...

★ ★ ☆ ☆ ☆

Patients with recurrent epithelial ovarian cancer can be treated with a ... study, Doxil Study 30-49, Gemcitabine versus PLD study), or these ... AGO- OVAR2.2), carboplatin + PLD (CALYPSO), or carboplatin + gem-citabine (AGO- OVAR, NCIG CTG, EORTC GCG trial) with or without bevacizumab (OCEANS). Topotecan Versus Paclitaxel (ten Bokkel, JCO 1997)

Therapeutic strategies in epithelial ovarian cancer ...

Clinical Trials in Ovarian Cancer - Project MUSE

★ ★ ☆ ☆ ☆

Most ovarian cancers are made of what celll type. Epithelial. Common Metastasis sites of ovarian cancer. ... Did the CALYPSO study show that carboplatin + paclitazel or cargo-latin + liposomal doxorubicin is better in platinum sensitive ovarian cancer pts. carboplatin plus liposomal doxorubicin.

Clinical Trials in Ovarian Cancer - Project MUSE

Ovarian Cancer Flashcards | Quizlet

★ ★ ★ ☆ ☆

Ovarian Cancer. Pancreatic Cancer ... results from a clinical study published in the March 2007 issue of the International Journal of Radiation Oncology Biology Physics1 demonstrated the Calypso 4D Localization System is a clinically efficient and objective localization method for positioning prostate patients undergoing radiation therapy ...

Ovarian Cancer Flashcards | Quizlet

Calypso | Upstate Cancer Center |SUNY Upstate Medical ...

★ ★ ☆ ☆ ☆

Targeted Chemotherapy for Ovarian Cancer with Homologous Recombination Deficiency of late relapse ... Study regimens and compliance in CALYPSO and MITO-2 Regimen Compliance MITO-2 PLD 30 mg/m2 + Carbo AUC 5, every 3 wks 81% completed 6 cycles …

Calypso | Upstate Cancer Center |SUNY Upstate Medical ...

Targeted chemotherapy for BRCA-Mutated Ovarian Cancer

★ ★ ★ ☆ ☆

9/1/2013 · The Role of Pegylated Liposomal Doxorubicin in Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials ... The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer 2006; 6: 5. ... Health-related quality of life in recurrent platinum-sensitive ovarian cancer—results from the CALYPSO trial.

Targeted chemotherapy for BRCA-Mutated Ovarian Cancer

The Role of Pegylated Liposomal Doxorubicin in Ovarian ...

★ ★ ☆ ☆ ☆

10/15/2012 · Papillary projections are characteristic of borderline tumors and Stage I primary invasive epithelial ovarian cancer. A small proportion of solid tissue at ultrasound examination makes a malignant mass more likely to be a borderline tumor or a Stage I epithelial ovarian cancer than an advanced ovarian cancer, a metastasis or a rare type of ...

The Role of Pegylated Liposomal Doxorubicin in Ovarian ...
Wada-test-fmri-study.html,Waiting-for-godot-study-quizlet.html,Wakefield-study-retracted.html,Wakewood-case-study.html,Walkley-black-titration-study.html